CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Regeneron Pharmaceuticals Inc REGN
News
Regeneron Announces Investor Conference Presentations
Regeneron Pharma 3Q Sales Climb on Dupixent Growth
Sanofi CEO Sets Sights on Deals to Drive Turnaround — 2nd Update
Regeneron Reports Third Quarter 2026 Financial and Operating Results
Sanofi CEO Sets Sights on Deals to Drive Turnaround — Update
Sanofi CEO Sets Sights on Deals to Drive Turnaround
Regeneron Secures $270 Million U.S. Contract Extension for Ebola Treatment Inmazeb
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal — Update
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action
United States